273 related articles for article (PubMed ID: 25968563)
21. Requirements for Parkinson's disease pharmacotherapy from the patients' perspective: a questionnaire-based survey.
Wüllner U; Fuchs G; Reketat N; Randerath O; Kassubek J
Curr Med Res Opin; 2012 Jul; 28(7):1239-46. PubMed ID: 22686959
[TBL] [Abstract][Full Text] [Related]
22. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
Fung VS; Herawati L; Wan Y; ;
Mov Disord; 2009 Jan; 24(1):25-31. PubMed ID: 18846551
[TBL] [Abstract][Full Text] [Related]
23. [Current possibilities of quality of life improvement in the late stages of Parkinson's disease].
Titova NV; Katunina EA
Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(3):94-100. PubMed ID: 26171484
[TBL] [Abstract][Full Text] [Related]
24. New treatments for the motor symptoms of Parkinson's disease.
Vijverman AC; Fox SH
Expert Rev Clin Pharmacol; 2014 Nov; 7(6):761-77. PubMed ID: 25318835
[TBL] [Abstract][Full Text] [Related]
25. [The new Parkinson's disease drugs].
Hasegawa K
Nihon Rinsho; 2000 Oct; 58(10):2066-71. PubMed ID: 11068448
[TBL] [Abstract][Full Text] [Related]
26. Safinamide for the treatment of Parkinson's disease.
Kandadai RM; Jabeen SA; Kanikannan MA; Borgohain R
Expert Rev Clin Pharmacol; 2014 Nov; 7(6):747-59. PubMed ID: 25300164
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease.
Müller T
Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):693-699. PubMed ID: 28537214
[TBL] [Abstract][Full Text] [Related]
28. Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease.
Antonini A; Mancini F; Canesi M; Zangaglia R; Isaias IU; Manfredi L; Pacchetti C; Zibetti M; Natuzzi F; Lopiano L; Nappi G; Pezzoli G
Neurodegener Dis; 2008; 5(3-4):244-6. PubMed ID: 18322402
[TBL] [Abstract][Full Text] [Related]
29. Treatment of levodopa-induced motor complications.
Stocchi F; Tagliati M; Olanow CW
Mov Disord; 2008; 23 Suppl 3():S599-612. PubMed ID: 18781681
[TBL] [Abstract][Full Text] [Related]
30. Parkinson's disease. Therapeutic strategies to improve patient function and quality of life.
Danisi F
Geriatrics; 2002 Mar; 57(3):46-50; quiz 52. PubMed ID: 11899548
[TBL] [Abstract][Full Text] [Related]
31. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of a once-daily extended-release formulation of pramipexole switched from an immediate-release formulation in patients with advanced Parkinson's disease: results from an open-label study.
Takanashi M; Shimo Y; Hatano T; Oyama G; Hattori N
Drug Res (Stuttg); 2013 Dec; 63(12):639-43. PubMed ID: 23884661
[TBL] [Abstract][Full Text] [Related]
33. [Treatment for advanced Parkinson's disease with intestinal levodopa/carbidopa gel: review of efficacy and safety].
Timofeeva AA
Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(11):145-51. PubMed ID: 25629138
[TBL] [Abstract][Full Text] [Related]
34. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
[TBL] [Abstract][Full Text] [Related]
35. Quality of life in Parkinson's disease--Indian scenario.
Ray J; Das SK; Gangopadhya PK; Roy T
J Assoc Physicians India; 2006 Jan; 54():17-21. PubMed ID: 16649733
[TBL] [Abstract][Full Text] [Related]
36. Duodenal levodopa/carbidopa infusion therapy in patients with advanced Parkinson's disease leads to improvement in caregivers' stress and burden.
Santos-García D; Añón MJ; Fuster-Sanjurjo L; de la Fuente-Fernández R
Eur J Neurol; 2012 Sep; 19(9):1261-5. PubMed ID: 22248261
[TBL] [Abstract][Full Text] [Related]
37. Treatment of early Parkinson's disease.
Pahwa R; Lyons KE
Curr Opin Neurol; 2014 Aug; 27(4):442-9. PubMed ID: 24950010
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study.
Durif F; Devaux I; Pere JJ; Delumeau JC; Bourdeix I;
Eur Neurol; 2001; 45(2):111-8. PubMed ID: 11244274
[TBL] [Abstract][Full Text] [Related]
39. New pharmacotherapy for Parkinson's disease.
Gottwald MD; Bainbridge JL; Dowling GA; Aminoff MJ; Alldredge BK
Ann Pharmacother; 1997 Oct; 31(10):1205-17. PubMed ID: 9337447
[TBL] [Abstract][Full Text] [Related]
40. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.
Olanow CW; Kieburtz K; Stern M; Watts R; Langston JW; Guarnieri M; Hubble J;
Arch Neurol; 2004 Oct; 61(10):1563-8. PubMed ID: 15477510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
